Find Hydroxypropyl-Beta Cyclodextrin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

JDMF

JDMFs Filed

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 107745-73-3, Hp-beta-cd, 2-hydroxypropyl-, A-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin, Trappsol hpb
Molecular Formula
C63H112O42
Molecular Weight
1541.5  g/mol
InChI Key
ODLHGICHYURWBS-LKONHMLTSA-N

Hydroxypropyl-Beta Cyclodextrin
Derivative of beta-cyclodextrin that is used as an excipient for steroid drugs and as a lipid chelator.
1 2D Structure

Hydroxypropyl-Beta Cyclodextrin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-5,10,15,20,25,30,35-heptakis(2-hydroxypropoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontane-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecol
2.1.2 InChI
InChI=1S/C63H112O42/c1-22(64)8-85-15-29-50-36(71)43(78)57(92-29)100-51-30(16-86-9-23(2)65)94-59(45(80)38(51)73)102-53-32(18-88-11-25(4)67)96-61(47(82)40(53)75)104-55-34(20-90-13-27(6)69)98-63(49(84)42(55)77)105-56-35(21-91-14-28(7)70)97-62(48(83)41(56)76)103-54-33(19-89-12-26(5)68)95-60(46(81)39(54)74)101-52-31(17-87-10-24(3)66)93-58(99-50)44(79)37(52)72/h22-84H,8-21H2,1-7H3/t22?,23?,24?,25?,26?,27?,28?,29-,30-,31-,32-,33-,34-,35-,36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,63-/m1/s1
2.1.3 InChI Key
ODLHGICHYURWBS-LKONHMLTSA-N
2.1.4 Canonical SMILES
CC(COCC1C2C(C(C(O1)OC3C(OC(C(C3O)O)OC4C(OC(C(C4O)O)OC5C(OC(C(C5O)O)OC6C(OC(C(C6O)O)OC7C(OC(C(C7O)O)OC8C(OC(O2)C(C8O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O)O
2.1.5 Isomeric SMILES
CC(COC[C@@H]1[C@@H]2[C@@H]([C@H]([C@H](O1)O[C@@H]3[C@H](O[C@@H]([C@@H]([C@H]3O)O)O[C@@H]4[C@H](O[C@@H]([C@@H]([C@H]4O)O)O[C@@H]5[C@H](O[C@@H]([C@@H]([C@H]5O)O)O[C@@H]6[C@H](O[C@@H]([C@@H]([C@H]6O)O)O[C@@H]7[C@H](O[C@@H]([C@@H]([C@H]7O)O)O[C@@H]8[C@H](O[C@H](O2)[C@@H]([C@H]8O)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)COCC(C)O)O)O)O
2.2 Synonyms
2.2.1 MeSH Synonyms

1. 2 Hydroxypropyl Beta Cyclodextrin

2. 2 Hydroxypropyl-beta-cyclodextrin

3. 2-hydroxypropyl-beta-cyclodextrin

4. Beta Hydroxypropylcyclodextrin

5. Beta-hydroxypropylcyclodextrin

6. Betadex, Hydroxypropyl

7. Hp-beta-cd

8. Hpbetacd

9. Hydroxypropyl Beta Cyclodextrin

10. Hydroxypropyl Betadex

11. Hydroxypropyl-beta-cyclodextrin

2.2.2 Depositor-Supplied Synonyms

1. 107745-73-3

2. Hp-beta-cd

3. 2-hydroxypropyl-

4. A-cyclodextrin

5. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrin

6. Trappsol Hpb

7. Hydroxypropylbetadex

8. Thpb

9. Hydroxypropyl-beta-cyclodextri

10. Hydroxypropyl-beta Cyclodextrin

11. Chembl577294

12. Dtxsid401017375

13. .beta.-cyclodextrin, 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-

14. 6a,6b,6c,6d,6e,6f,6g-heptakis-o-(2-hydroxypropyl)-beta-cyclodextrinr

2.3 Create Date
2007-02-09
3 Chemical and Physical Properties
Molecular Weight 1541.5 g/mol
Molecular Formula C63H112O42
XLogP3-13
Hydrogen Bond Donor Count21
Hydrogen Bond Acceptor Count42
Rotatable Bond Count28
Exact Mass1540.6628176 g/mol
Monoisotopic Mass1540.6628176 g/mol
Topological Polar Surface Area619 Ų
Heavy Atom Count105
Formal Charge0
Complexity2010
Isotope Atom Count0
Defined Atom Stereocenter Count35
Undefined Atom Stereocenter Count7
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Excipients

Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc. (See all compounds classified as Excipients.)


API SUPPLIERS

read-more
read-more

01

Gangwal Healthcare

India

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGangwal Healthcare is powered by innovation, driving health, wellness & healing.

Flag India
Digital Content Digital Content
USDMF CEP/COS JDMF EU-WCInactive-api NDC KDMF VMF Others AUDIT
Gangwal Healthcare CB

02

Roquette

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmatech Expo 2025
Not Confirmed
arrow

Roquette

France

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
USDMF arrow-down CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

03

Cyclo Therapeutics

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmatech Expo 2025
Not Confirmed
arrow

Cyclo Therapeutics

U.S.A

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
USDMF arrow-down CEP/COS JDMF EU-WC NDC KDMF VMF Others AUDIT
blank

04

Shandong Binzhou Zhiyuan Biotechno...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

Pharmatech Expo 2025
Not Confirmed
arrow

Shandong Binzhou Zhiyuan Biotechno...

China

USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

arrow
Pharmatech Expo 2025
Not Confirmed
USDMF CEP/COS arrow-down JDMF EU-WC NDC KDMF VMF Others AUDIT
blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

USDMF

read-more
read-more

01

Pharmatech Expo 2025
Not Confirmed

01

Pharmatech Expo 2025
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 28889

Submission : 2014-12-30

Status : Active

Type : II

blank

02

Roquette Freres

France

USDMF

arrow
Pharmatech Expo 2025
Not Confirmed
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

CEP/COS

read-more
read-more

01

Pharmatech Expo 2025
Not Confirmed
arrow

02

Pharmatech Expo 2025
Not Confirmed
arrow
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

EU WC

read-more
read-more

01

arrow
Pharmatech Expo 2025
Not Confirmed
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothGangwal Healthcare is powered by innovation, driving health, wellness & healing.

Flag India
Digital Content Digital Content

Hydroxypropyl Betadex BP/USP/EP

Date of Issue : 2022-07-08

Valid Till : 2024-11-04

Written Confirmation Number : WC-0432

Address of the Firm : Plot No N·5, MIDC, Boisar, Tal Palghar, Dist- Thane, 401506, Maharashtra

Gangwal Healthcare CB
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

NDC API

read-more
read-more

01

Pharmatech Expo 2025
Not Confirmed
arrow
arrow
Pharmatech Expo 2025
Not Confirmed

HYDROXYPROPYL BETADEX

NDC Package Code : 73212-043

Start Marketing Date : 2022-01-03

End Marketing Date : 2025-12-31

Dosage Form (Strength) : POWDER (1g/g)

Marketing Category : BULK INGREDIENT

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger August 22, 2024

blank

01

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The combined company will focus on the development of Trappsol Cyclo (hydroxypropyl-beta cyclodextrin) for the treatment of Niemann-Pick Disease Type C1.

Brand Name : Trappsol Cyclo

Molecule Type : Small molecule

Upfront Cash : Undisclosed

August 22, 2024

blank

Details:

Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Small molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 30, 2024

blank

02

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Trappsol Cyclo (hydroxypropyl betacyclodextrin) is being evaluated for the treatment of systemic and neurological symptoms of Niemann-Pick Disease Type C1.

Brand Name : Trappsol Cyclo

Molecule Type : Small molecule

Upfront Cash : Not Applicable

May 30, 2024

blank

Details:

VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Nephrology Brand Name: VAR 200

Study Phase: Phase IProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 18, 2024

blank

03

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is being developed to mediate removal of excess cholesterol that damages the kidneys’ filtration system in patients with Diabetic Kidney Disease.

Brand Name : VAR 200

Molecule Type : Large molecule

Upfront Cash : Not Applicable

March 18, 2024

blank

Details:

The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger December 27, 2023

blank

04

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

December 27, 2023

blank

Details:

Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 18, 2023

blank

05

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Trappsol Cyclo is a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in phase 3 clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease.

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

December 18, 2023

blank

Details:

VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alport syndrome.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Nephrology Brand Name: VAR 200

Study Phase: Phase IProduct Type: Large molecule

Sponsor: George Clinical

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable December 14, 2023

blank

06

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : VAR 200 (2-hydroxypropyl-beta-cyclodextrin, 2HPβCD) is a phase 2a-ready drug in development which has potential to treat multiple kidney diseases, including diabetic kidney disease, rare kidney diseases, FSGS (focal segmental glomerulosclerosis) and Alp...

Brand Name : VAR 200

Molecule Type : Large molecule

Upfront Cash : Not Applicable

December 14, 2023

blank

Details:

The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type C1 (NPC1).


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Cyclo Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger September 21, 2023

blank

07

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : The combined company will focus on advancing Cyclo Therapeutics’ pivotal Phase 3 global study evaluating Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, for Niemann-Pick Disease Type ...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

September 21, 2023

blank

Details:

Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal and Alzheimer’s disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Rafael Holdings

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement August 02, 2023

blank

08

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Cyclo Therapeutics intends to use the proceeds to support of its Trappsol Cyclo, a proprietary formulation of hydroxypropyl beta cyclodextrin being developed in clinical trials for the potential treatment of Niemann-Pick Disease Type C1, a rare, fatal an...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

August 02, 2023

blank

Details:

Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fatal genetic disease.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Rafael Holdings

Deal Size: $5.0 million Upfront Cash: Undisclosed

Deal Type: Private Placement June 05, 2023

blank

09

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Cyclo Therapeutics intends to use the proceeds for the support of its Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug designated product in the United States and Europe, under clinical trial for Niemann-Pick Disease Type C, a rare and fa...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Undisclosed

June 05, 2023

blank

Details:

Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease and NPC1.


Lead Product(s): Hydroxypropyl-Beta Cyclodextrin

Therapeutic Area: Rare Diseases and Disorders Brand Name: Trappsol Cyclo

Study Phase: Phase IIIProduct Type: Large molecule

Sponsor: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 11, 2023

blank

10

Pharmatech Expo 2025
Not Confirmed
Pharmatech Expo 2025
Not Confirmed

Details : Trappsol® Cyclo™ (hydroxypropyl beta cyclodextrin), effectively manages the transportation of cholesterol accumulated out of the cells by taking the place of the defective NPC1 protein. It is currently being evaluated for Early Alzheimer’s Disease a...

Brand Name : Trappsol Cyclo

Molecule Type : Large molecule

Upfront Cash : Not Applicable

January 11, 2023

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

Others

read-more
read-more

01

USP

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

USP

U.S.A
arrow
Pharmatech Expo 2025
Not Confirmed

Hydroxypropyl Betadex (200 mg)

CAS Number : 128446-35-5

Quantity Per Vial : 200

Sale Unit : mg

Price : $275.00

Details : USMCA- No; KORUS- No

Monograph :

Storage :

Code/Batch No : Catalog #1329709

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

ABOUT THIS PAGE

Hydroxypropyl-Beta Cyclodextrin Manufacturers

A Hydroxypropyl-Beta Cyclodextrin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Hydroxypropyl-Beta Cyclodextrin, including repackagers and relabelers. The FDA regulates Hydroxypropyl-Beta Cyclodextrin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Hydroxypropyl-Beta Cyclodextrin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Hydroxypropyl-Beta Cyclodextrin Suppliers

A Hydroxypropyl-Beta Cyclodextrin supplier is an individual or a company that provides Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) or Hydroxypropyl-Beta Cyclodextrin finished formulations upon request. The Hydroxypropyl-Beta Cyclodextrin suppliers may include Hydroxypropyl-Beta Cyclodextrin API manufacturers, exporters, distributors and traders.

click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.

Hydroxypropyl-Beta Cyclodextrin USDMF

A Hydroxypropyl-Beta Cyclodextrin DMF (Drug Master File) is a document detailing the whole manufacturing process of Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) in detail. Different forms of Hydroxypropyl-Beta Cyclodextrin DMFs exist exist since differing nations have different regulations, such as Hydroxypropyl-Beta Cyclodextrin USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Hydroxypropyl-Beta Cyclodextrin DMF submitted to regulatory agencies in the US is known as a USDMF. Hydroxypropyl-Beta Cyclodextrin USDMF includes data on Hydroxypropyl-Beta Cyclodextrin's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Hydroxypropyl-Beta Cyclodextrin USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with USDMF on PharmaCompass.

Hydroxypropyl-Beta Cyclodextrin CEP

A Hydroxypropyl-Beta Cyclodextrin CEP of the European Pharmacopoeia monograph is often referred to as a Hydroxypropyl-Beta Cyclodextrin Certificate of Suitability (COS). The purpose of a Hydroxypropyl-Beta Cyclodextrin CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Hydroxypropyl-Beta Cyclodextrin EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Hydroxypropyl-Beta Cyclodextrin to their clients by showing that a Hydroxypropyl-Beta Cyclodextrin CEP has been issued for it. The manufacturer submits a Hydroxypropyl-Beta Cyclodextrin CEP (COS) as part of the market authorization procedure, and it takes on the role of a Hydroxypropyl-Beta Cyclodextrin CEP holder for the record. Additionally, the data presented in the Hydroxypropyl-Beta Cyclodextrin CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Hydroxypropyl-Beta Cyclodextrin DMF.

A Hydroxypropyl-Beta Cyclodextrin CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Hydroxypropyl-Beta Cyclodextrin CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.

click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with CEP (COS) on PharmaCompass.

Hydroxypropyl-Beta Cyclodextrin WC

A Hydroxypropyl-Beta Cyclodextrin written confirmation (Hydroxypropyl-Beta Cyclodextrin WC) is an official document issued by a regulatory agency to a Hydroxypropyl-Beta Cyclodextrin manufacturer, verifying that the manufacturing facility of a Hydroxypropyl-Beta Cyclodextrin active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Hydroxypropyl-Beta Cyclodextrin APIs or Hydroxypropyl-Beta Cyclodextrin finished pharmaceutical products to another nation, regulatory agencies frequently require a Hydroxypropyl-Beta Cyclodextrin WC (written confirmation) as part of the regulatory process.

click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with Written Confirmation (WC) on PharmaCompass.

Hydroxypropyl-Beta Cyclodextrin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Hydroxypropyl-Beta Cyclodextrin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Hydroxypropyl-Beta Cyclodextrin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Hydroxypropyl-Beta Cyclodextrin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Hydroxypropyl-Beta Cyclodextrin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Hydroxypropyl-Beta Cyclodextrin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Hydroxypropyl-Beta Cyclodextrin suppliers with NDC on PharmaCompass.

Hydroxypropyl-Beta Cyclodextrin GMP

Hydroxypropyl-Beta Cyclodextrin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Hydroxypropyl-Beta Cyclodextrin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Hydroxypropyl-Beta Cyclodextrin GMP manufacturer or Hydroxypropyl-Beta Cyclodextrin GMP API supplier for your needs.

Hydroxypropyl-Beta Cyclodextrin CoA

A Hydroxypropyl-Beta Cyclodextrin CoA (Certificate of Analysis) is a formal document that attests to Hydroxypropyl-Beta Cyclodextrin's compliance with Hydroxypropyl-Beta Cyclodextrin specifications and serves as a tool for batch-level quality control.

Hydroxypropyl-Beta Cyclodextrin CoA mostly includes findings from lab analyses of a specific batch. For each Hydroxypropyl-Beta Cyclodextrin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Hydroxypropyl-Beta Cyclodextrin may be tested according to a variety of international standards, such as European Pharmacopoeia (Hydroxypropyl-Beta Cyclodextrin EP), Hydroxypropyl-Beta Cyclodextrin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Hydroxypropyl-Beta Cyclodextrin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty